Literature DB >> 32115668

Nonavalent Human Papillomavirus Vaccination as a Treatment for Skin Warts in Immunosuppressed Adults: A Case Series.

Simon Bossart1, Valentina Imstepf, Robert E Hunger, S Morteza Seyed Jafari.   

Abstract

Entities:  

Keywords:  immunosuppressed patients; nonavalent; skin warts; human papillomavirus vaccination

Mesh：

Substances：

Year:  2020        PMID： 32115668      PMCID： PMC9128913          DOI： 10.2340/00015555-3437

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  14 in total

1.  Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Authors:  Matti Lehtinen; Jorma Paavonen; Cosette M Wheeler; Unnop Jaisamrarn; Suzanne M Garland; Xavier Castellsagué; S Rachel Skinner; Dan Apter; Paulo Naud; Jorge Salmerón; Song-Nan Chow; Henry Kitchener; Júlio C Teixeira; James Hedrick; Genara Limson; Anne Szarewski; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; Newton S De Carvalho; Maria Julieta V Germar; Klaus Peters; Adrian Mindel; Philippe De Sutter; F Xavier Bosch; Marie-Pierre David; Dominique Descamps; Frank Struyf; Gary Dubin
Journal:  Lancet Oncol       Date:  2011-11-08       Impact factor: 41.316

2.  Recalcitrant cutaneous warts treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, and 18) in a developmentally delayed, 31-year-old white man.

Authors:  Supriya S Venugopal; Dedee F Murrell
Journal:  Arch Dermatol       Date:  2010-05

3.  Quadrivalent human papillomavirus vaccination: a promising treatment for recalcitrant cutaneous warts in children.

Authors:  Dietrich Abeck; Regina Fölster-Holst
Journal:  Acta Derm Venereol       Date:  2015-11       Impact factor: 4.437

4.  Recalcitrant plantar warts treated with recombinant quadrivalent human papillomavirus vaccine.

Authors:  Megan N Landis; Donald P Lookingbill; Jason C Sluzevich
Journal:  J Am Acad Dermatol       Date:  2012-08       Impact factor: 11.527

5.  Complete resolution of chronic multiple verruca vulgaris treated with quadrivalent human papillomavirus vaccine.

Authors:  Benjamin S Daniel; Dedee F Murrell
Journal:  JAMA Dermatol       Date:  2013-03       Impact factor: 10.282

Review 6.  Papillomavirus infections--a major cause of human cancers.

Authors:  H zur Hausen
Journal:  Biochim Biophys Acta       Date:  1996-10-09

7.  Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.

Authors:  R Kirnbauer; L M Chandrachud; B W O'Neil; E R Wagner; G J Grindlay; A Armstrong; G M McGarvie; J T Schiller; D R Lowy; M S Campo
Journal:  Virology       Date:  1996-05-01       Impact factor: 3.616

Review 8.  Laser Treatment of Nongenital Verrucae: A Systematic Review.

Authors:  Jannett Nguyen; Dorota Z Korta; Lance W Chapman; Kristen M Kelly
Journal:  JAMA Dermatol       Date:  2016-09-01       Impact factor: 10.282

9.  Nonavalent human papillomavirus vaccination as a treatment for warts in an immunosuppressed adult.

Authors:  Sara B Ferguson; Elisa S Gallo
Journal:  JAAD Case Rep       Date:  2017-07-26

10.  Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.

Authors:  Warner K Huh; Elmar A Joura; Anna R Giuliano; Ole-Erik Iversen; Rosires Pereira de Andrade; Kevin A Ault; Deborah Bartholomew; Ramon M Cestero; Edison N Fedrizzi; Angelica L Hirschberg; Marie-Hélène Mayrand; Angela Maria Ruiz-Sternberg; Jack T Stapleton; Dorothy J Wiley; Alex Ferenczy; Robert Kurman; Brigitte M Ronnett; Mark H Stoler; Jack Cuzick; Suzanne M Garland; Susanne K Kjaer; Oliver M Bautista; Richard Haupt; Erin Moeller; Michael Ritter; Christine C Roberts; Christine Shields; Alain Luxembourg
Journal:  Lancet       Date:  2017-09-05       Impact factor: 79.321
View more
  2 in total

1.  Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis: A Nonrandomized Clinical Trial.

Authors:  Jana Smahelova; Eva Hamsikova; Viera Ludvikova; Jitka Vydrova; Joseph Traboulsi; Ondrej Vencalek; Petr Lukeš; Ruth Tachezy
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2022-07-01       Impact factor: 8.961

2.  Vaccines and dermatology: Expanding the role of dermatology clinics in the name of public health.

Authors:  Charles Dunn; Yasser Faraj; Nicole Vesely; Michael Foss; Austin Ambur; Rajiv Nathoo
Journal:  JAAD Int       Date:  2022-06-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.